352 related articles for article (PubMed ID: 14550806)
1. Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions.
Burt RK; Drobyski WR; Seregina T; Traynor A; Oyama Y; Keever-Taylor C; Stefka J; Kuzel TM; Brush M; Rodriquez J; Burns W; Tennant L; Link C
Exp Hematol; 2003 Oct; 31(10):903-10. PubMed ID: 14550806
[TBL] [Abstract][Full Text] [Related]
2. Herpes simplex thymidine kinase (HStk) transgenic donor lymphocytes.
Burt RK; Drobyski WR; Traynor AE; Link CJ
Bone Marrow Transplant; 1999 Nov; 24(10):1043-51. PubMed ID: 10578153
[TBL] [Abstract][Full Text] [Related]
3. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation?
Tiberghien P; Reynolds CW; Keller J; Spence S; Deschaseaux M; Certoux JM; Contassot E; Murphy WJ; Lyons R; Chiang Y
Blood; 1994 Aug; 84(4):1333-41. PubMed ID: 8049449
[TBL] [Abstract][Full Text] [Related]
4. Production and culture of HSVtk transduced suicidal lymphocytes induces variable changes in the lymphocyte subset composition.
Marini FC; Kornblau SM
Bone Marrow Transplant; 1999 May; 23(9):907-15. PubMed ID: 10338046
[TBL] [Abstract][Full Text] [Related]
5. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir.
Munshi NC; Govindarajan R; Drake R; Ding LM; Iyer R; Saylors R; Kornbluth J; Marcus S; Chiang Y; Ennist D; Kwak L; Reynolds C; Tricot G; Barlogie B
Blood; 1997 Feb; 89(4):1334-40. PubMed ID: 9028956
[TBL] [Abstract][Full Text] [Related]
6. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
7. Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation.
Ho VT; Kim HT; Kao G; Cutler C; Levine J; Rosenblatt J; Joyce R; Antin JH; Soiffer RJ; Ritz J; Avigan D; Alyea EP
Am J Hematol; 2014 Dec; 89(12):1092-6. PubMed ID: 25132538
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
9. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
10. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
11. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.
Yan CH; Xu LP; Liu DH; Chen H; Wang Y; Wang JZ; Wang FR; Han W; Liu KY; Huang XJ
Clin Transplant; 2015 Jul; 29(7):594-605. PubMed ID: 25969866
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction. HGTRI 0103.
Link CJ; Burt RK; Traynor AE; Drobyski WR; Seregina T; Levy JP; Gordon L; Rosen ST; Burns WH; Camitta B; Casper J; Horowitz M; Juckett M; Lawton C; Margolis D; Pietryga D; Rowlings P; Taylor C; Furtado M; Stefka J; Gupta-Burt S; Kaiser H; Vesole DH
Hum Gene Ther; 1998 Jan; 9(1):115-34. PubMed ID: 9458247
[TBL] [Abstract][Full Text] [Related]
13. Infusion of donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene for recurrent hematologic malignancies after allogeneic hematopoietic stem cell transplantation.
Hashimoto H; Kitano S; Ueda R; Ito A; Tada K; Fuji S; Yamashita T; Tomura D; Nukaya I; Mineno J; Fukuda T; Mori S; Takaue Y; Heike Y
Int J Hematol; 2015 Jul; 102(1):101-10. PubMed ID: 25948083
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
15. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Giralt S; Hester J; Huh Y; Hirsch-Ginsberg C; Rondón G; Seong D; Lee M; Gajewski J; Van Besien K; Khouri I; Mehra R; Przepiorka D; Körbling M; Talpaz M; Kantarjian H; Fischer H; Deisseroth A; Champlin R
Blood; 1995 Dec; 86(11):4337-43. PubMed ID: 7492795
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
[TBL] [Abstract][Full Text] [Related]
17. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies.
Traversari C; Marktel S; Magnani Z; Mangia P; Russo V; Ciceri F; Bonini C; Bordignon C
Blood; 2007 Jun; 109(11):4708-15. PubMed ID: 17327417
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation.
Koster EAS; von dem Borne PA; van Balen P; Marijt EWA; Tjon JML; Snijders TJF; van Lammeren D; Veelken H; Falkenburg JHF; Halkes CJM; de Wreede LC
Front Immunol; 2024; 15():1335341. PubMed ID: 38545096
[TBL] [Abstract][Full Text] [Related]
19. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
20. Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation.
Ciceri F; Bonini C; Gallo-Stampino C; Bordignon C
Cytotherapy; 2005; 7(2):144-9. PubMed ID: 16040393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
